A Study to Evaluate the Effectiveness and Safety of Larazotide Acetate for the Relief of CeD Symptoms

Overview

About this study

The purpose of this study is to assess the effectiveness and safety of larazotide acetate versus placebo for the relief of persistent symptoms in adult celiac disease patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male and female adults diagnosed with celiac disease (positive celiac serology plus confirmed biopsy) for at least 6 months.
  • On a gluten-free diet for at least 6 months.
  • Experiencing symptoms (i.e., abdominal pain, abdominal cramping, bloating, gas, diarrhea, loose stool, or nausea).
  • Willing to maintain current gluten-free diet throughout participation in the study. 

Exclusion Criteria:

  • Refractory celiac disease or severe complications of celiac disease.
  • Chronic active GI disease other than celiac disease.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Joseph Murray, M.D.

Closed for enrollment

Contact information:

Carol Van Dyke CCRP

(507) 266-7842

VanDyke.Carol@mayo.edu

More information

Publications

Publications are currently not available